NCT01898117: Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Bevacizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

NCT01898117
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Chemotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Senior
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with previous cytotoxic therapy for metastatic disease; Patients with known CNS disease except for treated brain metastases
https://ClinicalTrials.gov/show/NCT01898117

Comments are closed.

Up ↑